NCT02174523View on ClinicalTrials.gov

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Schizophrenia
Interventions
DRUG

40mg lurasidone

DRUG

placebo

Trial Locations (1)

200031

Xuhui Center Hospital, Shanghai

All Listed Sponsors
collaborator

Xuhui Central Hospital, Shanghai

OTHER

lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT02174523 - Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects | Biotech Hunter | Biotech Hunter